PRESS RELEASE published on 06/13/2025 at 07:30, 9 months 9 days ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
PRESS RELEASE published on 06/13/2025 at 07:30, 9 months 9 days ago Informations privilégiées / Autres communiqués MaaT Pharma présente des données actualisées positives pour Xervyteg® lors du Congrès de l’EHA confirmant une forte efficacité observée dans l’étude pivotale ARES dans la maladie aiguë du greffon contre l’hôte Thérapie MaaT Pharma AGvH Xervyteg EHA
BRIEF published on 05/12/2025 at 07:35, 10 months 10 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 05/12/2025 at 07:35, 10 months 10 days ago Données prometteuses pour MaaT033 dans la SLA Microbiome Sclérose Latérale Amyotrophique MaaT033 Sécurité Et Tolérabilité Essai Clinique Phase 1b
PRESS RELEASE published on 05/12/2025 at 07:30, 10 months 10 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 11 months 14 days ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
BRIEF published on 04/08/2025 at 07:35, 11 months 14 days ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 11 months 14 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
PRESS RELEASE published on 04/08/2025 at 07:30, 11 months 14 days ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 11 months 15 days ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
Published on 03/20/2026 at 13:30, 2 days 11 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 12 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 12 hours 37 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 2 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 3 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 3 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 6 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 6 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 6 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 6 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
